Recent years have seen great progress in assigning specific DUBs to biological pathways and in understanding the structural underpinning of their activity, specificity and regulation. Moreover, DUBs are emerging as a novel class of druggable targets in cancer, neurodegeneration, infection and inflammation. This conference will provide the first international meeting dedicated to this class of enzymes, encompassing structural, physiological and translational aspects. It will bring together international leaders in the field together with early stage researchers, in a setting and atmosphere aimed at fostering collegiality and collaboration. In addition to invited speakers, a number of talks will be selected from the submitted abstracts.